Issue to be Considered by FDA Advisory Committee on November 21, 2024, and Discussion May Lead to Andexxa Drug Recall
(Posted by Tom Lamb at Drug Injury Watch)
At its November 21, 2024 meeting, the FDA’s Cellular,
Law Offices of Thomas J. Lamb, P.A.
Website:
https://www.drug-injury.com/
Law Offices of Thomas J. Lamb, P.A. Blogs
Blog Authors
Latest from Law Offices of Thomas J. Lamb, P.A.
Side Effects of Birth Control: Brain Tumors Related to Depo-Provera Contraceptive Injections
By Tom Lamb
Intracranial Meningioma Risks Are Increased When Depo-Provera Was Used for More Than One Year
(Posted by Tom Lamb at Drug Injury Watch)
A medical journal article published in March 2024 reported that Depo-Provera (medroxyprogesterone acetate) increased the…
Plaintiffs Win the Latest Round in Long-Running Fosamax Femur Fracture Litigation
By Tom Lamb
Federal Appeals Court Rejects Merck’s Legal Defense of Federal Preemption in September 2024
(Posted by Tom Lamb at Drug Injury Watch)
A federal appeals court ruled in September 2024 that more than 500 plaintiffs should have their…
Veozah Liver Injury Drug Safety Communication Issued by FDA in September 2024
By Tom Lamb
August 2024 Veozah Drug Label Change Adds Warnings About Liver Toxicity and Abnormal Liver Tests
(Posted by Tom Lamb at Drug Injury Watch)
On September 12, 2024, the FDA announced a warning about the rare occurrence of…
Syfovre Injections Side Effects Legal Compensation Cases Being Filed for Patients
By Tom Lamb
Drug Company Apellis Failed to Warn About Retinal Vasculitis Until a November 2023 Label Change
(Posted by Tom Lamb at Drug Injury Watch)
We are handling Syfovre injections side effects legal compensation cases being filed for patients…
No Warnings About Blood Clots From Ozempic, Wegovy, and Rybelsus in Drug Labels
By Tom Lamb
Growing Number of Pulmonary Embolism and DVT Cases Involving Semaglutide Reported by Patients
(Posted by Tom Lamb at Drug Injury Watch)
Wegovy, Rybelsus, and Ozempic have been associated with an increased risk of blood clots that can…
Wegovy, Rybelsus, and Ozempic Eye Side Effects: Semaglutide Linked to NAION
By Tom Lamb
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), or “Eye Stroke”, Can Cause Vision Loss
(Posted by Tom Lamb at Drug Injury Watch)
Wegovy, Rybelsus, and Ozempic eye side effects are possible given the recent findings that the active…
Syfovre Safety-Benefit Assessment by Europe’s Drug Regulator Differs From FDA
By Tom Lamb
EMA’s CHMP Does Not Approve Syfovre for a Second Time, Citing “significant risk of adverse events”
(Posted by Tom Lamb at Drug Injury Watch)
There seems to be some disagreement about the Syfovre safety-benefit assessment when it…
Wegovy, Rybelsus, and Ozempic Blood Clots Cases Are Not Part of Federal Court MDL at This Time
By Tom Lamb
Semaglutide-related Side Effects Include Ischemic Stroke, Pulmonary Embolism, and Deep Vein Thrombosis
(Posted by Tom Lamb at Drug Injury Watch)
Wegovy, Rybelsus, and Ozempic are drugs with semaglutide as their active ingredient. Semaglutide is associated with a…
Syfovre Retinal Vaso-occlusive Vasculitis Case Report Involving 78-year Old Woman With Vision Loss
By Tom Lamb
She Went to the Local ER With Loss of Vision 11 Days After Receiving an Intravitreal Syfovre (Pegcetacoplan) Injection
(Posted by Tom Lamb at Drug Injury Watch)
In the March 2024 edition of the American Journal of…